Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy

Breast Cancer Research and Treatment

Volumn 95, Issue 1, 2006, Pages 13-16

  Grabinski, J L ^a,e   Smith, L S ^b   Chisholm, G B ^d   Drengler, R ^b   Rodriguez, G I ^b   Lang, A S ^b   Kalter, S P ^b   Garner, A M ^b   Fichtel, L M ^b   Hollsten, J ^b   Pollock, B H ^d,e   Kuhn, J G ^a,c,e  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Center for Epidemiology and Biostatistics   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Allelic frequency; Early stage breast cancer; Genotypic frequency; Polymorphism; SULT1A1

Indexed keywords

SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CAUCASIAN; EXON; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 32444447357     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9019-5     Document Type: Article

References (10)

1. Falany C, Wheeler J, Oh T, Falany J: Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 48(4): 369-375, 1994
2. Weinshilboum R, Otterness D, Aksoy I, Wood T, Her C, Raftogianis R: Sulfotransferase molecular biology: cDNAs and genes. FASEB 11: 3-14, 1997
3. Raftogianis R, Wood T, Otterness D, Van Loon J, Weinshilboum R: Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239: 298-304, 1997
4. Nowell S, Ambrosone C, Ozawa S, MacLeod S, Mrackova G, Williams S, Plaxco J, Kadlubar F, Lang N: Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics 10: 789-797, 2000
5. Carlini E, Raftogianis R, Wood T, Jin F, Zheng W, Rebbeck T, Weinshilboum R: Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11: 57-68, 2001
6. Coughtrie M, Gilissen A, Shek B, Strange R, Fryer A, Jones P, Bamber D: Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 337: 45-49, 1999
7. Seth P, Lunetta K, Bell D, Gray H, Nasser S, Rhei E, Kaelin C, Iglehart D, Marks J, Garber J, et al.: Phenol sulfotransferases:Hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60: 6859-6863, 2000
8. Zheng W, Xie D, Cerhan J, Sellers T, Wen W, Folsom A: Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10: 89-94, 2001
9. Nowell S, Sweeney C, Winters M, Stone A, Lang N, Hutchins L, Kadlubar F, Ambrosone C: Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94(21): 1635-1640, 2002
10. Ozawa S, Tang Y-M, Yamzoe Y, Kato R, Lang N, Kadlubar F: Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact 109: 237-248, 1998